Peptides News and Research

RSS

Promising compound blocks production of beta amyloid peptides in Alzheimer's mouse model

Offering a potential early intervention for Alzheimer's disease (AD), researchers at University of California, San Diego School of Medicine and Cenna Biosciences, Inc. have identified compounds that block the production of beta amyloid peptides in mice.

30 Apr 2015

Yale researchers successfully correct gene mutation that causes cystic fibrosis

Yale researchers successfully corrected the most common mutation in the gene that causes cystic fibrosis, a lethal genetic disorder. The study was published April 27 in Nature Communications.

28 Apr 2015

Glide's solid dose formulation of teriparatide achieves successful results in pre-clinical study

Glide Technologies, the development company focused on solid dose formulations of therapeutics and vaccines and non-invasive diagnostics, today announced that its novel solid dose formulation of teriparatide (parathyroid hormone) achieved successful results in a pre-clinical proof-of-concept study comparing it with the currently marketed liquid product (Forteo/Forsteo).

24 Apr 2015

Glide's solid dose formulation of teriparatide achieves successful results in pre-clinical study

24 Apr 2015

Diabetes drug liraglutide could prove to be a new treatment option for NASH

A drug approved to treat type 2 diabetes could prove to be a powerful new treatment option for non-alcoholic steatohepatitis (NASH), according to research presented today at The International Liver Congress 2015. Results from a randomised controlled trial showed liraglutide met the primary endpoint of histological clearance of NASH, and a reduction in the progression of fibrosis.

23 Apr 2015

Novel treatment strategy targets treatment-resistant CML

Researchers have shown that the coiled-coil mimetic CCmut3 can inhibit cell growth and promote apoptosis in cell lines expressing BCR–ABL1, including those resistant to tyrosine kinase inhibitors.

20 Apr 2015

New set of molecules could carry medicines into cells

Just as a scientist dressed in a lab coat and goggles might get stuck behind the velvet rope at a trendy bar, many otherwise good drugs can't get inside cells if they don't look the part. In a report published this week in ACS Central Science, researchers report a new set of molecules that could ferry medicines into cells by taking on the right charge and shape, easily sliding past lipid membranes.

16 Apr 2015

SELLAS inks exclusive global collaboration, license agreement with TrojanTec

SELLAS Life Sciences Group, a Swiss based, development-stage biopharmaceutical company with its main focus in developing innovative products for the treatment of various indications in Oncology and the Central Nervous System, today announced that it has signed an exclusive global collaboration and license agreement with TrojanTec Ltd, a UK-based Discovery Research and Development Company affiliated with Imperial College London, UK, for the development, marketing and commercialization of the innovative and proprietary TR-1 cancer therapeutic technology and drug.

15 Apr 2015

JPK reports on the use of the NanoWizard® 3 AFM system at the Hebrew University of Jerusalem

JPK Instruments, a world-leading manufacturer of nanoanalytic instrumentation for research in life sciences and soft matter, reports on the use of their NanoWizard® AFM system in the Institute of Chemistry of the Hebrew University of Jerusalem...

From Bruker Nano Surfaces and Metrology 14 Apr 2015

Research opens door to potential drug target for deadly Ebola virus

Opening the door to potential treatments for the deadly Ebola virus, scientists have found that a protein made by the virus plays a role similar to that of a coat-check attendant.

9 Apr 2015

UAB scientists create alternative to the use of viruses in gene therapy

A team of scientists from the Institute for Biotechnology and Biomedicine at the UAB has produced an alternative to the use of viruses in gene therapy. The researchers synthesised nanoparticles which act as artificial viruses, capable of surrounding DNA fragments and releasing them as therapeutic agents, with no biological risk, into the interior of the cells.

9 Apr 2015

Plymouth researchers receive grant to develop effective therapy for Huntington's disease

Huntington's disease is an hereditary disorder of the nervous system caused by a faulty gene on chromosome four. The faulty gene leads to nerve damage in the area of the brain resulting in gradual physical, mental and emotional changes. Those born to a parent with Huntington's disease have a 50:50 chance of developing it, and there is currently no cure.

9 Apr 2015

Rhythm, Actavis announce initiation of relamorelin Phase 2b trial for treatment of diabetic gastroparesis

Rhythm, a biopharmaceutical company, and Actavis plc, a leading global pharmaceutical company, announced today the initiation of a Phase 2b clinical trial assessing the efficacy and safety of relamorelin (RM-131), Rhythm's ghrelin agonist, for the treatment of gastroparesis in patients with type 1 and type 2 diabetes.

8 Apr 2015

Cerapedics closes $4 million term loan, raises additional $4 million in equity financing

Cerapedics, a privately-held orthobiologics company, today announced closing of a $4 million term loan from GE Capital, Healthcare Financial Services, bringing the total facility to $16.5 million. The company also announced it recently raised an additional $4 million in equity financing from inside investors.

7 Apr 2015

Personalized cancer vaccines can be used to marshal powerful immune response

Personalized melanoma vaccines can be used to marshal a powerful immune response against unique mutations in patients' tumors, according to early data in a first-in-people clinical trial at Washington University School of Medicine in St. Louis.

6 Apr 2015

Astellas Pharma, MD Anderson sign option agreement to research and develop new treatment for AML

Astellas Pharma Inc. and The University of Texas MD Anderson Cancer Center today announced the signing of an option agreement to research and develop a new treatment for patients with acute myeloid leukemia (AML).

6 Apr 2015

A new amyloid-targeting treatment for Alzheimer's disease

With each new amyloid-targeting treatment for Alzheimer's disease that has been developed, there has been a corresponding concern. For example, antibodies targeting amyloid-β peptide (Aβ) produce inflammation in the brain in some patients.

3 Apr 2015

MRSA bacteria exposed to cigarette smoke become more resistant to antimicrobial peptides

Methicillin-resistant Staphylococcus aureus (MRSA), an antibiotic-resistant superbug, can cause life-threatening skin, bloodstream and surgical site infections or pneumonia. Researchers at the University of California, San Diego School of Medicine now report that cigarette smoke may make matters worse.

3 Apr 2015

New enzymatically active, ultrathin pepsin membrane splits proteins, separates products

Novel enzymatically active membranes can complete two steps in one: they can enzymatically split proteins and simultaneously separate the products.

2 Apr 2015

Penn Med's BLINKER Team named one of 16 finalists in NIH 'Follow that Cell Challenge'

James Eberwine, PhD, the Elmer Holmes Bobst Professor of Systems Pharmacology and Experimental Therapeutics, at the Perelman School of Medicine at the University of Pennsylvania, was named one of 16 finalists in the first phase of the Follow that Cell Challenge funded by the National Institutes of Health. The competition was run by crowdsourcing company Innocentive and 687 designated "solvers" entered initially.

2 Apr 2015

Peptides News and Research

Promising compound blocks production of beta amyloid peptides in Alzheimer's mouse model

Yale researchers successfully correct gene mutation that causes cystic fibrosis

Glide's solid dose formulation of teriparatide achieves successful results in pre-clinical study

Glide's solid dose formulation of teriparatide achieves successful results in pre-clinical study

Diabetes drug liraglutide could prove to be a new treatment option for NASH

Novel treatment strategy targets treatment-resistant CML

New set of molecules could carry medicines into cells

SELLAS inks exclusive global collaboration, license agreement with TrojanTec

JPK reports on the use of the NanoWizard® 3 AFM system at the Hebrew University of Jerusalem

Research opens door to potential drug target for deadly Ebola virus

UAB scientists create alternative to the use of viruses in gene therapy

Plymouth researchers receive grant to develop effective therapy for Huntington's disease

Rhythm, Actavis announce initiation of relamorelin Phase 2b trial for treatment of diabetic gastroparesis

Cerapedics closes $4 million term loan, raises additional $4 million in equity financing

Personalized cancer vaccines can be used to marshal powerful immune response

Astellas Pharma, MD Anderson sign option agreement to research and develop new treatment for AML

A new amyloid-targeting treatment for Alzheimer's disease

MRSA bacteria exposed to cigarette smoke become more resistant to antimicrobial peptides

New enzymatically active, ultrathin pepsin membrane splits proteins, separates products

Penn Med's BLINKER Team named one of 16 finalists in NIH 'Follow that Cell Challenge'

Editorial Focus eBook - Peptides and Oligonucleotides (2nd edition) eBook

The Critical Role of Sample Storage in Drug Discovery and Development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

Latest News